FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
November 11, 2026
Foley Viewpoints
Data Center Development Faces a New Reality as Public Scrutiny Grows
As AI continues to fuel demand for data centers, growing public scrutiny, regulatory uncertainty, power constraints, and tighter capital markets are raising the bar for development. Here’s what developers and investors should consider as the market enters its next phase.
November 10, 2026
Foley Viewpoints
Tariff-ied! – Substantial Transformation
Substantial transformation rules determine when processing or manufacturing changes a product’s country of origin, generally requiring a significant change in name, character, or use compared with its inputs.
November 10, 2026
Foley Viewpoints
Where Will the Physical AI Patent Wars Begin?
The next autonomy patent wars may not be confined to cars. As AI moves into drones, robots, defense systems, warehouses, and industrial equipment, the collision between software, sensors, connectivity, and physical control may create new licensing and litigation flashpoints.